Improving Prognostication in Pulmonary Hypertension Using AI-quantified Fibrosis and Radiologic Severity Scoring at Baseline CT.

Background There is clinical need to better quantify lung disease severity in pulmonary hypertension (PH), particularly in idiopathic pulmonary arterial hypertension (IPAH) and PH associated with lung disease (PH-LD). Purpose To quantify fibrosis on CT pulmonary angiograms using an artificial intelligence (AI) model and to assess whether this approach can be used in combination with radiologic scoring to predict survival. Materials and Methods This retrospective multicenter study included adult patients with IPAH or PH-LD who underwent incidental CT imaging between February 2007 and January 2019. Patients were divided into training and test cohorts based on the institution of imaging. The test cohort included imaging examinations performed in 37 external hospitals. Fibrosis was quantified using an established AI model and radiologically scored by radiologists. Multivariable Cox regression adjusted for age, sex, World Health Organization functional class, pulmonary vascular resistance, and diffusing capacity of the lungs for carbon monoxide was performed. The performance of predictive models with or without AI-quantified fibrosis was assessed using the concordance index (C index). Results The training and test cohorts included 275 (median age, 68 years [IQR, 60-75 years]; 128 women) and 246 (median age, 65 years [IQR, 51-72 years]; 142 women) patients, respectively. Multivariable analysis showed that AI-quantified percentage of fibrosis was associated with an increased risk of patient mortality in the training cohort (hazard ratio, 1.01 [95% CI: 1.00, 1.02]; P = .04). This finding was validated in the external test cohort (C index, 0.76). The model combining AI-quantified fibrosis and radiologic scoring showed improved performance for predicting patient mortality compared with a model including radiologic scoring alone (C index, 0.67 vs 0.61; P < .001). Conclusion Percentage of lung fibrosis quantified on CT pulmonary angiograms by an AI model was associated with increased risk of mortality and showed improved performance for predicting patient survival when used in combination with radiologic severity scoring compared with radiologic scoring alone. © RSNA, 2024 Supplemental material is available for this article.

[1]  S. Alabed,et al.  A transparent artificial intelligence framework to assess lung disease in pulmonary hypertension , 2023, Scientific Reports.

[2]  M. Humbert,et al.  2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. , 2022, European heart journal.

[3]  Robert A. Lewis,et al.  Computed tomography lung parenchymal descriptions in routine radiological reporting have diagnostic and prognostic utility in patients with idiopathic pulmonary arterial hypertension and pulmonary hypertension associated with lung disease , 2022, ERJ Open Research.

[4]  D. Kiely,et al.  Assessing pulmonary hypertension severity in lung disease is a key step to improving outcomes: embrace resistance and don't be pressurised to go with the flow , 2021, European Respiratory Journal.

[5]  S. Rosenkranz,et al.  Pulmonary vascular resistance predicts mortality in patients with pulmonary hypertension associated with interstitial lung disease: results from the COMPERA registry , 2021, European Respiratory Journal.

[6]  B. Maron,et al.  Elevated pulmonary vascular resistance predicts mortality in COPD patients , 2021, European Respiratory Journal.

[7]  E. Hoffman,et al.  Pulmonary Hypertension in Association with Lung Disease: Quantitative CT and Artificial Intelligence to the Rescue? State-of-the-Art Review , 2021, Diagnostics.

[8]  H. Olschewski The Challenge to Decide between Pulmonary Hypertension Due to Chronic Lung Disease and PAH with Chronic Lung Disease , 2021, Diagnostics.

[9]  Jonathan H. Chung,et al.  Practical Imaging Interpretation in Patients Suspected of Having Idiopathic Pulmonary Fibrosis: Official Recommendations from the Radiology Working Group of the Pulmonary Fibrosis Foundation , 2021, Radiology. Cardiothoracic imaging.

[10]  Robert A. Lewis,et al.  Mild parenchymal lung disease is still lung disease , 2020, European Respiratory Journal.

[11]  L. Harbaum,et al.  Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry. , 2020, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[12]  M. Lidén,et al.  Interobserver variability in high-resolution CT of the lungs , 2020, European journal of radiology open.

[13]  Robert A. Lewis,et al.  Mild parenchymal lung disease and/or low diffusion capacity impacts survival and treatment response in patients diagnosed with idiopathic pulmonary arterial hypertension , 2020, European Respiratory Journal.

[14]  R. Benza,et al.  Predicting Survival in Patients With Pulmonary Arterial Hypertension: The REVEAL Risk Score Calculator 2.0 and Comparison With ESC/ERS-Based Risk Assessment Strategies. , 2019, Chest.

[15]  E. V. van Beek,et al.  Statement on imaging and pulmonary hypertension from the Pulmonary Vascular Research Institute (PVRI) , 2019, Pulmonary circulation.

[16]  C. Ryerson,et al.  Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis , 2018, European Respiratory Journal.

[17]  Anand Devaraj,et al.  Role of imaging in progressive-fibrosing interstitial lung diseases , 2018, European Respiratory Review.

[18]  T. Welte,et al.  More on idiopathic pulmonary arterial hypertension with a low diffusing capacity , 2017, European Respiratory Journal.

[19]  D. Hansell,et al.  Mortality prediction in idiopathic pulmonary fibrosis: evaluation of computer-based CT analysis with conventional severity measures , 2017, European Respiratory Journal.

[20]  T. Welte,et al.  Diffusion Capacity and Mortality in Patients With Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction. , 2016, JACC. Heart failure.

[21]  D. Hansell,et al.  Interobserver agreement for the ATS/ERS/JRS/ALAT criteria for a UIP pattern on CT , 2015, Thorax.

[22]  N. Westerhof,et al.  Severely reduced diffusion capacity in idiopathic pulmonary arterial hypertension: patient characteristics and treatment responses , 2013, European Respiratory Journal.

[23]  D. Lynch,et al.  Interobserver variability in the CT assessment of honeycombing in the lungs. , 2013, Radiology.

[24]  J. Wild,et al.  Pulmonary hypertension in COPD: results from the ASPIRE registry , 2012, European Respiratory Journal.

[25]  N. Müller,et al.  Fleischner Society: glossary of terms for thoracic imaging. , 2008, Radiology.

[26]  J. Butler,et al.  Variability of routine pulmonary function tests. , 1975, Thorax.